Centessa Pharmaceuticals plc — Director's Dealing 2025

Dec 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2025-12-08

Reporting Person: Accardi Mario Alberto (President, Orexin Program)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-08	Ordinary Shares	M	5000	$9.53	Acquired	198801	Direct
2025-12-08	Ordinary Shares	S	10000	$30	Disposed	188801	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-08	Share Option (right to buy)	$9.53	M	5000	Disposed	2032-02-01	Ordinary Shares (5000)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025.

F3: 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments with the first installment vesting on March 1, 2022.